Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $11.57 and traded as low as $10.60. Mesoblast shares last traded at $10.85, with a volume of 106,288 shares changing hands.
Analyst Ratings Changes
Several analysts have issued reports on the company. Piper Sandler reissued an "overweight" rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Mesoblast currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Check Out Our Latest Stock Report on Mesoblast
Mesoblast Trading Down 2.4%
The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The company has a 50 day simple moving average of $11.40 and a 200-day simple moving average of $13.94.
Institutional Investors Weigh In On Mesoblast
Hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC raised its holdings in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after purchasing an additional 901 shares during the period. R Squared Ltd purchased a new stake in Mesoblast in the fourth quarter worth $30,000. Prosperity Wealth Management Inc. increased its position in Mesoblast by 2.0% in the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after buying an additional 1,795 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of Mesoblast by 41.1% in the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after buying an additional 1,891 shares during the period. Finally, Barclays PLC bought a new position in shares of Mesoblast during the 4th quarter worth $38,000. 1.43% of the stock is currently owned by institutional investors.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
